North America Peptide Therapeutics Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type (Generic, Innovative); Route of Administration (Parenteral, Oral, Mucosal, Pulmonary, Others); Synthesis Technology (Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Technology); Application (Cancer, Cardiovascular Disorder, Metabolic Disorder, Respiratory Disorder, Pain, Dermatology), and Country

No. of Pages: 98    |    Report Code: TIPRE00020133    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Peptide Therapeutics Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. North America Peptide Therapeutics Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. North America Peptide Therapeutics Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 Growing Investments on Peptide Therapeutics
5.2 Market Opportunities
  • 5.2.1 Operational Limitations of Peptides
5.3 Future Trends
  • 5.3.1 Emphasis on Automatic Peptide Synthesis
5.4 Impact of Drivers and Restraints

6. North America Peptide Therapeutics Market Regional Analysis

6.1 North America Peptide Therapeutics Market Overview
6.2 North America Peptide Therapeutics Market Revenue 2017-2027 (US$ Million)
6.3 North America Peptide Therapeutics Market Forecast Analysis

7. North America Peptide Therapeutics Market Analysis – by Type

7.1 Generic
  • 7.1.1 Overview
  • 7.1.2 Generic: North America Peptide Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Innovative
  • 7.2.1 Overview
  • 7.2.2 Innovative: North America Peptide Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Peptide Therapeutics Market Analysis – by Route of Administration

8.1 Parenteral
  • 8.1.1 Overview
  • 8.1.2 Parenteral: North America Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.2 Oral
  • 8.2.1 Overview
  • 8.2.2 Oral: North America Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.3 Mucosal
  • 8.3.1 Overview
  • 8.3.2 Mucosal: North America Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Pulmonary
  • 8.4.1 Overview
  • 8.4.2 Pulmonary: North America Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

9. North America Peptide Therapeutics Market Analysis – by Synthesis Technology

9.1 Solid Phase Peptide Synthesis
  • 9.1.1 Overview
  • 9.1.2 Pulmonary: North America Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.2 Liquid Phase Peptide Synthesis
  • 9.2.1 Overview
  • 9.2.2 Pulmonary: North America Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.3 Hybrid Technology
  • 9.3.1 Overview
  • 9.3.2 Pulmonary: North America Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)

10. North America Peptide Therapeutics Market – North America Analysis

10.1 North America
  • 10.1.1 North America Peptide Therapeutics Market Breakdown, by Key Country, 2020 and 2027 (%)
  • 10.1.1.1 North America Peptide Therapeutics Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 US: North America Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.1.1 US: North America Peptide Therapeutics Market Breakdown, by Type
    • 10.1.1.1.2 US: North America Peptide Therapeutics Market Breakdown, by Route of Administration
    • 10.1.1.1.3 US: North America Peptide Therapeutics Market Breakdown, by Synthesis Technology
  • 10.1.1.2 Canada: North America Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.2.1 Canada: North America Peptide Therapeutics Market Breakdown, by Type
    • 10.1.1.2.2 Canada: North America Peptide Therapeutics Market Breakdown, by Route of Administration
    • 10.1.1.2.3 Canada: North America Peptide Therapeutics Market Breakdown, by Synthesis Technology
  • 10.1.1.3 Mexico : North America Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
    • 10.1.1.3.1 Mexico : North America Peptide Therapeutics Market Breakdown, by Type
    • 10.1.1.3.2 Mexico : North America Peptide Therapeutics Market Breakdown, by Route of Administration
    • 10.1.1.3.3 Mexico : North America Peptide Therapeutics Market Breakdown, by Synthesis Technology

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. North America Peptide Therapeutics Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Amgen Inc.
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Eli Lilly and Company
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 EVER Pharma GmbH
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Polypeptide Group
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 TEVA PHARMACEUTICAL INDUSTRIES LTD
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 AstraZeneca
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Bristol-Myers Squibb Company
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 GlaxoSmithKline plc
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 Novo Nordisk A/S
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
13.10 Sanofi
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - North America Peptide Therapeutics Market

  1. Amgen Inc.
  2. Eli Lilly and Company
  3. EVER Pharma GmbH
  4. Polypeptide Group
  5. TEVA PHARMACEUTICAL INDUSTRIES LTD
  6. AstraZeneca
  7. Bristol-Myers Squibb Company
  8. GlaxoSmithKline plc
  9. Novo Nordisk A/S
  10. Sanofi
north-america-peptide-therapeutics-market